) formed a partnership with leading pharmaceutical companies -
Cubist Pharmaceuticals, Inc.
) to revolutionize infectious disease therapy through the
development of a rapid diagnostic test that can target multi-drug
resistant bacteria and support the proper use of antibiotics.
The collaboration of Cepheid is aimed at identification of the
right treatment method that can target bacterial infections to
subside the development of resistance. Recognizing the need to
arrest the crisis of antibiotic resistance, the consortium has
focused its attention on Xpert Carba-R as the much-desired
Following the news, Cepheid's share price rose 1.4% to
eventually close at $47.78 on Friday.
According to a 2013 report by the US Centers for Disease Control
and Prevention (CDC), almost 50% of all prescribed antimicrobial
agents are unnecessary or ineffective. This has induced the
evolution of multiple species of bacteria that have become
resistant to many, and in some cases, all of the antimicrobial
agents used for bacterial infection therapy.
In the U.S. alone, more than 2 million people each year contract
serious bacterial infections that are resistant to one or more of
the antimicrobial agents used for treatment.
What is Xpert Carba-R?
Xpert Carba-R is a molecular test used for rapid and accurate
detection of carbapenemase-producing (resistant) gram-negative
bacteria. It uses rectal swab samples to identify the presence of
potentially life threatening bacteria in an individual.
At present, this diagnostic test is under development in the
U.S. but is commercially available outside the U.S. It is set for a
commercial release in the U.S. in 2015, subject to regulatory
Right now, the consortium is engaged in expanding the number of
body sample types from rectal swabs to other body samples such as
respiratory samples taken from pneumonia patients.
Recently, Cepheid released Xpert Carba-R diagnostic test in
Europe, to be marketed as a CE IVD product under the European
Directive on In Vitro Diagnostic Medical Devices. The test runs on
Cepheid's GeneXpert System, the world's leading molecular
This diagnostic test can detect patients carrying
carbapenemase-producing microorganisms in less than one hour. Fast
and accurate identification will help physicians control the spread
of infection in patients more effectively by prescribing suitable
Management of Cepheid and other three healthcare organizations
are of the opinion that such a rapid diagnostic test will
facilitate the development of a new pipeline of pathogen-targeted
antibacterials, the administration of the right drug to the
concerned patient and lesser clinical trial complications.
Currently, Cepheid, AstraZeneca, Cubist and GlaxoSmithKline, all
carry a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis
CEPHEID INC (CPHD): Free Stock Analysis Report
CUBIST PHARM (CBST): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis
To read this article on Zacks.com click here.